keyword
MENU ▼
Read by QxMD icon Read
search

Plegridy

keyword
https://www.readbyqxmd.com/read/25941954/peginterferon-beta-1a-plegridy-for-multiple-sclerosis
#1
REVIEW
(no author information available yet)
Pegylated interferon beta-1a (Plegridy) injected subcutaneously every 2 weeks appears to be similar in its efficacy and adverse effects to older interferon formulations that must be injected more frequently.
May 11, 2015: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/25666445/peginterferon-beta-1a-a-review-of-its-use-in-patients-with-relapsing-remitting-multiple-sclerosis
#2
REVIEW
Sheridan M Hoy
Peginterferon beta-1a (Plegridy™), an interferon beta-1a conjugated to a methoxy polyethylene glycol (PEG) molecule, is available in the EU and the USA for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS). In a 96-week multinational, phase III study in this patient population (ADVANCE), subcutaneous peginterferon beta-1a 125 µg every 2 weeks significantly reduced the adjusted annualized relapse rate over 48 weeks, compared with placebo, corresponding to 36% fewer relapses per patient-year...
February 2015: CNS Drugs
https://www.readbyqxmd.com/read/25466632/ifn-%C3%AE-and-multiple-sclerosis-from-etiology-to-therapy-and-back
#3
REVIEW
V Annibali, R Mechelli, S Romano, M C Buscarinu, A Fornasiero, R Umeton, V A G Ricigliano, F Orzi, E M Coccia, M Salvetti, G Ristori
Several immunomodulatory treatments are currently available for relapsing-remitting forms of multiple sclerosis (RRMS). Interferon beta (IFN) was the first therapeutic intervention able to modify the course of the disease and it is still the most used first-line treatment in RRMS. Though two decades have passed since IFN-β was introduced in the management of MS, it remains a valid approach because of its good benefit/risk profile. This is witnessed by new efforts of pharmaceutical industry to improve this line: a PEGylated form of subcutaneous IFN-β 1a, (Plegridy(®)) with a longer half-life, has been recently approved in RRMS...
April 2015: Cytokine & Growth Factor Reviews
https://www.readbyqxmd.com/read/25336862/pharmaceutical-approval-update
#4
Kunj Gohil
Idelalisib (Zydelig) for certain types of leukemia and lymphoma, peginterferon beta-1a (Plegridy) for relapsing forms of multiple sclerosis, and suvorexant (Belsomra) for insomnia.
October 2014: P & T: a Peer-reviewed Journal for Formulary Management
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"